Baker Bros. Advisors 13F: Adds $922K to IRON Stake

Baker Bros. Advisors Boosts Disc Medicine Holding

Baker Bros. Advisors expanded its investment in Disc Medicine, Inc. (NasdaqGM: IRON) according to a recent Form 13F filing with the SEC. The fund lifted its holdings by 12,607 shares during the period ended May 15, 2026, bringing its total ownership to 349,657 shares. This 3.7% increase left the fund with a stake valued at roughly $25.57 million based on filings for the reporting window. Because 13F reports look backward, these figures reflect holdings as of that specific date and may not match the firm's exact position today.

Disc Medicine Stock Trades Near Moving Averages

Shares of Disc Medicine traded around $73.14 on Sunday. The biotech stock has seen wide swings over the past year, trading as low as $40.00 and reaching a high of $99.50. Its current price sits close to its 200-day moving average of $73.03 and just below its 50-day moving average of $76.60.

Insider Buying and Selling at Disc Medicine, Inc.

Recent weeks brought a series of insider transactions at the company, building on earlier reports of executive trades. On June 26, 2026, Chief Legal Officer Rahul Khara bought 851 shares at an average price of $14.69 for a total of $12,501.19. This followed an earlier purchase by Khara on June 18, 2026, when he picked up 7,500 shares at $14.69 each worth $110,175. Other executives also made moves in mid-June, including Chief Operating Officer Yu Jonathan Yen-Wen acquiring 18,612 shares on June 16, 2026, at $9.86 apiece for $183,514.32, before later selling 9,700 shares on June 22, 2026. Nadim Ahmed and Liam Ratcliffe also acquired shares on June 18, 2026.

Wall Street Analysts Keep Upbeat Ratings

Analyst firms remain largely positive on the clinical-stage biotechnology company's pipeline. On September 16, 2026, Wells Fargo maintained its Overweight rating while boosting its price target to $86.00 from $79.00. Wedbush followed on September 10, 2026, reiterating an Outperform rating with a $100.00 target, after having raised its target from $88.00 on September 2, 2026. HC Wainwright & Co. kept a Buy rating with a $120.00 target on August 6, 2026. Overall, the stock carries a strong buy consensus rating from twelve analysts, with a mean price target of $103.17.

Focusing on Hematologic Diseases

Disc Medicine is a clinical-stage biopharmaceutical firm based in Watertown, Massachusetts. The company develops treatments for serious blood disorders, focusing on biological pathways like heme biosynthesis and iron homeostasis. Its product candidates target conditions such as erythropoietic porphyrias, myelofibrosis, and polycythemia vera.

What to Watch at Disc Medicine, Inc.

Investors can check subsequent SEC filings to see if Baker Bros. Advisors adjusts its position further. The company's next earnings report is expected on November 5, 2026, which will provide updated financial results for the clinical-stage enterprise.